%PDF-1.4
%
124 0 obj
<>
endobj
121 0 obj
<>
endobj
187 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T16:08:33Z
2024-03-29T04:19:34-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T04:19:34-07:00
application/pdf
Heather
2001-70 april02
uuid:f5281be1-1dd1-11b2-0a00-680827fd5800
uuid:f5281be4-1dd1-11b2-0a00-6a0000000000
endstream
endobj
110 0 obj
<>
endobj
111 0 obj
<>
endobj
125 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
43 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
61 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
84 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
97 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
221 0 obj
[225 0 R]
endobj
222 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57.3333 714.5293 Tm
[(16.)-500.1 (Caldenhoven E, Liden J, )17.7 (W)39.7 (issink S, et al. Negative cross-talk)]TJ
0 Tc 1.75 -1.25 Td
[(beween RelA)-220.1 (and the glucocorticoid receptor: a possible mechanism)]TJ
0 -1.25 TD
(for the antiinflammatory action of glucocorticoids. Mol Endocrinol)Tj
0 Tw T*
(1995;9:401-12.)Tj
0.02499 Tw -1.75 -1.25 Td
[(17.)-500 (Han CW)91.8 (, Choi JH, Kim JM, et al. Glucocorticoid-mediated)]TJ
1.75 -1.25 Td
(repression of inflammatory cytokine production in fibroblast-like)Tj
T*
[(rheumatoid synoviocytes is independent of nuclear factor)19.8 (-kappa B)]TJ
T*
(activation induced by tumor necrosis factor alpha. Rheumatology)Tj
0 Tw T*
(2001;40:267-73.)Tj
0.0249 Tw -1.75 -1.25 Td
[(18.)-500 (Brostjan C, )54.8 (Anrather J, Csizmadia )17.7 (V)129.2 (, et al. Glucocorticoid-mediated)]TJ
-0.00011 Tc 1.75 -1.25 Td
(repression of NF-)Tj
/T1_0 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/TT0 1 Tf
0.02499 Tw [0.2 (B activity in endothelial cells does not involve)]TJ
T*
(induction of I)Tj
/T1_0 1 Tf
0 Tw 5.4929 0 Td
(\002)Tj
/TT0 1 Tf
[0.2 (B)]TJ
/T1_0 1 Tf
(\003)Tj
/TT0 1 Tf
0.02499 Tw 2.1217 0 Td
(synthesis. J Biol Chem 1996;271:19612-6.)Tj
-0.00011 Tc -9.3646 -1.25 Td
[(19.)-500.1 (Kumkumian GK, Lafyatis R, Remmers EF)79.7 (, et al. Platelet-derived)]TJ
0 Tc 1.75 -1.25 Td
(growth factor and IL-1 interactions in rheumatoid arthritis.)Tj
T*
(Regulation of synoviocyte proliferation, prostaglandin production,)Tj
T*
(and collagenase transcription. J Immunol 1989;143:833-7.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(20.)-500.1 (Schreiber E, Matthias P)110.7 (, Muller MM, Schaf)17.7 (fner )17.7 (W)91.7 (.)-0.1 ( Rapid detection)]TJ
1.75 -1.25 Td
(of octamer binding proteins with \221mini-extracts\222, prepared from a)Tj
0 Tc T*
[(small number of cells. Nucleic )54.9 (Acid Res 1989;17:6419.)]TJ
-1.75 -1.25 Td
[(21.)-500 (Handel ML, Gir)17.8 (gis L. Concepts of pathogenesis and emer)17.8 (ging)]TJ
-0.00011 Tc 1.75 -1.25 Td
[(treatments in rheumatic diseases: transcription factors. Bailliere\222)54.8 (s)]TJ
0 Tc T*
(Best Practice & Research. Clin Rheumatol 2001;15:657-75. )Tj
-1.75 -1.25 Td
[(22.)-500 (Crof)17.8 (ford LJ, )17.7 (T)69.8 (an B, McCarthy CJ, Hla )17.7 (T)74 (. Involvement of nuclear)]TJ
-0.00011 Tc 0 Tw 1.75 -1.25 Td
(factor )Tj
/T1_0 1 Tf
0 Tc 2.6061 0 Td
(\002)Tj
/TT0 1 Tf
0.02499 Tw [0.2 (B in the regulation of cyclooxygenase-2 expression by)]TJ
-2.6061 -1.25 Td
[(interleukin-1 in rheumatoid synoviocytes. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1997;40:226-36.)Tj
0.02499 Tw -1.75 -1.25 Td
[(23.)-500 (Lehmann )17.8 (TP)110.8 (, Nguyen LQQ, Handel ML. Synovial fluid-induced)]TJ
-0.00011 Tc 1.75 -1.25 Td
[(nuclear factor)19.7 (-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 5.8612 0 Td
(\002)Tj
/TT0 1 Tf
0.0249 Tw [0.2 (B DNA)-220.1 (binding in a monocytic cell line. )]TJ
-5.8612 -1.25 Td
(J Rheumatol 2000;27:2769-76.)Tj
-1.75 -1.25 Td
[(24.)-500 (Collantes E, )17.8 (V)111.1 (alle Blazquez M, Mazorra )17.8 (V)129.1 (, et al. Nuclear factor)19.8 (-)]TJ
1.75 -1.25 Td
[(kappa B in )17.8 (T)-257.2 (cells from patients with rheumatic diseases: a)]TJ
T*
[(preliminary report. )54.8 (Ann Rheum Dis 1998;57:738-41.)]TJ
-1.75 -1.25 Td
[(25.)-500 (W)79.8 (akisaka S, Suzuki N, )17.8 (T)69.8 (akeno M, et al. Involvement of)]TJ
1.75 -1.25 Td
(simultaneous multiple transcription factor expression, including)Tj
T*
[(cAMP)-238.1 (responsive element binding protein and OCT)91.8 (-1, for synovial)]TJ
T*
[(cell outgrowth in patients with rheumatoid arthritis. )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(1998;57:487-94.)Tj
0.02499 Tw -1.75 -1.25 Td
[(26.)-500 (Aupperle KR, Bennett BL, Boyle DL, et al. NF-kappa B regulation)]TJ
1.75 -1.25 Td
(by I kappa B kinase in primary fibroblast-like synoviocytes. J)Tj
T*
(Immunol 1999;163:427-33.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(27.)-500.1 (Alaeddine N, Di Battista JA, Pelletier J-P)110.7 (, et al. Inhibition of tumor)]TJ
1.75 -1.25 Td
(necrosis factor )Tj
/T1_0 1 Tf
0 Tc 0 Tw [0.1 (\003)]TJ
/TT0 1 Tf
0.02499 Tw [0.2 (-induced prostaglandin E)]TJ
0 Tw 5.2 0 0 5.2 206.4537 301.8893 Tm
(2)Tj
0.02499 Tw 8 0 0 8 211.2537 304.5293 Tm
(production by the)Tj
-17.4901 -1.25 Td
(antiinflammatory cytokines interleukin-4, interleukin-10, and)Tj
T*
[(interleukin-13 in osteoarthritic synovial fibroblasts. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1999;42:710-8.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(28.)-500.1 (Li P)110.7 (, Sanz I, O\222Keefe RJ, Schwarz EM. NF-kappa B regulates)]TJ
1.75 -1.25 Td
(VCAM-1 expression on fibroblast-like synoviocytes. J Immunol)Tj
0 Tc 0 Tw T*
(2000;164:5990-7.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(29.)-500.1 (Asahara H, )54.8 (Asanuma M, Ogawa N, Nishibayashi S, Inoue H. High)]TJ
1.75 -1.25 Td
(DNA-binding activity of transcription factor NF-)Tj
/T1_0 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/TT0 1 Tf
0.02499 Tw [0.2 (B in synovial)]TJ
T*
(membranes of patients with rheumatoid arthritis. Biochem Mol Biol)Tj
T*
(Int 1995;37:827-32.)Tj
-1.75 -1.25 Td
[(30.)-500 (Fujisawa K, )54.8 (Aono H, Hasunuma )17.7 (T)74 (, et al. )54.8 (Activation of transcription)]TJ
-0.00011 Tc 1.75 -1.25 Td
(factor NF-)Tj
/T1_0 1 Tf
0 Tc 0 Tw [0.2 (\002)]TJ
/TT0 1 Tf
0.02499 Tw [0.2 (B in human synovial cells in response to tumor necrosis)]TJ
-0.00011 Tc 0 Tw T*
(factor )Tj
/T1_0 1 Tf
0 Tc 2.6061 0 Td
(\003)Tj
/TT0 1 Tf
0.02499 Tw [0.2 (. )54.9 (Arthritis Rheum 1996;39:197-203.)]TJ
28.6439 67.5 Td
[(31.)-500 (Sato M, Miyazaki )17.7 (T)74 (,)0.1 ( Kambe F)79.8 (, Maeda K, Seo H. Quercetin, a)]TJ
1.75 -1.25 Td
(bioflavonoid, inhibits the induction of interleukin 8 and monocyte)Tj
T*
[(chemoattractant protein-1 expression by tumor necrosis factor)19.8 (-alpha)]TJ
T*
(in cultured human synovial cells. J Rheumatol 1997;24:1680-4.)Tj
-1.75 -1.25 Td
[(32.)-500 (Y)100.1 (o)0.1 (shida S, Kato )17.7 (T)74 (, Sakurada S, et al. Inhibition of IL-6 and IL-8)]TJ
1.75 -1.25 Td
(induction from cultured rheumatoid synovial fibroblasts by)Tj
T*
[(treatment with aurothioglucose. Int Immunol 1999;1)36.9 (1:151-8.)]TJ
-1.75 -1.25 Td
[(33.)-500 (Jeon KI, Jeong JY)128.9 (, Jue DM. )17.7 (Thiol-reactive metal compounds inhibit)]TJ
1.75 -1.25 Td
(NF-kappa B activation by blocking I kappa B kinase. J Immunol)Tj
0 Tw T*
(2000;164:5981-9.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(34.)-500.1 (Steer JH, Kroeger KM, )54.8 (Abraham LJ, Joyce DA. Glucocorticoids)]TJ
1.75 -1.25 Td
[(suppress tumor necrosis factor)19.7 (-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw (\003)Tj
/TT0 1 Tf
0.02499 Tw 13.4829 0 Td
(expression by human monocytic)Tj
-0.00011 Tc -13.4828 -1.25 Td
(THP-1 cells by suppressing transactivation through adjacent NF-)Tj
/T1_0 1 Tf
0 Tc 0 Tw 26.1384 0 Td
(\002)Tj
/TT0 1 Tf
[0.2 (B)]TJ
0.02499 Tw -26.1384 -1.25 Td
[(and c-Jun-activating transcription factor)19.8 (-2 binding sites in the)]TJ
T*
[(promoter)54.9 (. J Biol Chem 2000;275:18432-40.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(35.)-500.1 (Gerlach DM, Ransone L, )17.7 (T)69.7 (ak PP)110.7 (, et al. )17.7 (The ef)17.7 (fects of a )17.7 (T)-257.3 (cell-)]TJ
1.75 -1.25 Td
(specific NF-)Tj
/T1_0 1 Tf
0 Tc 0 Tw [0.2 (\002)]TJ
/TT0 1 Tf
0.02499 Tw [0.2 (B inhibitor on in vitro cytokine production and)]TJ
T*
(collagen-induced arthritis. J Immunol 2000;165:1652-8.)Tj
-1.75 -1.25 Td
[(36.)-500 (Miyazawa K, Mori )54.8 (A, Okudaira H. Regulation of )]TJ
1.75 -1.25 Td
(interleukin-1\337-induced interleukin-6 gene expression in human)Tj
T*
(fibroblast-like synoviocytes by glucocorticoids. J Biochem)Tj
0 Tw T*
[(1998;124:1)36.9 (130-7.)]TJ
0.0249 Tw -1.75 -1.25 Td
[(37.)-500 (Migita K, )17.7 (T)69.8 (anaka H, Okamoto K, et al. FK506 augments)]TJ
1.75 -1.25 Td
(glucocorticoid-mediated cyclooxygenase-2 downregulation in)Tj
T*
(human rheumatoid synovial fibroblasts. Lab Invest 2000;80:135-41.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(38.)-500.1 (Handel ML. )17.7 (T)34.8 (ranscription factors )54.8 (AP-1 and NF-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 21.201 0 Td
(\002)Tj
/TT0 1 Tf
-0.00011 Tc 0.00729 Tw [0.2 (B: Where )-17.7 (steroids)]TJ
0 Tc 0.02499 Tw -19.4511 -1.25 Td
(meet the gold standard of anti-rheumatic drugs. Inflamm Res)Tj
0 Tw T*
(1997;46:282-6.)Tj
0.02499 Tw -1.75 -1.25 Td
[(39.)-500 (Handel ML, Nguyen LQQ, Lehmann )17.8 (TP)110.9 (. Inhibition of transcription)]TJ
1.75 -1.25 Td
(factors by antiinflammatory and antirheumatic drugs: Can variability)Tj
T*
(in response be overcome. Clin Exp Pharmacol Physiol 2000;)Tj
0 Tw T*
(27:139-44.)Tj
0.0249 Tw -1.75 -1.25 Td
[(40.)-500 (Y)100.1 (ang JP)110.8 (, Merin JP)110.9 (, Nakano )17.7 (T)74 (, et al. Inhibition of the DNA-binding)]TJ
1.75 -1.25 Td
(activity of NF-kappa B by gold compounds in vitro. FEBS Letts)Tj
0 Tw T*
(1995;361:89-96.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(41.)-500.1 (Kopp E, Ghosh S. Inhibition of NF-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 16.287 0 Td
(\002)Tj
/TT0 1 Tf
0.02499 Tw [0.2 (B by sodium salicylate and)]TJ
-14.537 -1.25 Td
(aspirin. Science 1994;265:956-9.)Tj
-1.75 -1.25 Td
[(42.)-500 (W)79.8 (ahl C, Liptay S, )54.9 (Adler G, Schmid RM. Sulfasalazine: a potent and)]TJ
1.75 -1.25 Td
(specific inhibitor of nuclear factor kappa B. J Clin Invest)Tj
0 Tw T*
[(1998;101:1)36.9 (163-74.)]TJ
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(43.)-500.1 (Manna SK, )54.8 (Aggarwal BB. Immunosuppressive leflunomide )]TJ
0 Tc 1.75 -1.25 Td
[(metabolite \(A77 1726\) blocks )17.7 (TNF-dependent nuclear factor)19.8 (-)]TJ
/T1_0 1 Tf
0 Tw 24.7679 0 Td
(\002)Tj
/TT0 1 Tf
[0.2 (B)]TJ
0.02499 Tw -24.768 -1.25 Td
(activation and gene expression. J Immunol 1999;162:2095-102.)Tj
-1.75 -1.25 Td
[(44.)-500 (Handel ML, )17.7 (W)79.8 (atts CKW)91.8 (, deFazio )54.8 (A, Day RO, Sutherland RL.)]TJ
1.75 -1.25 Td
[(Inhibition of )54.9 (AP-1 binding and transcription by gold and selenium)]TJ
T*
(involving conserved cysteine residues in Jun and Fos. Proc Natl)Tj
T*
[(Acad Sci USA)-220.1 (1995;92:4497-501.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(45.)-500.1 (Handel ML, )17.7 (W)79.7 (atts CKW)91.7 (, Sivertsen S, Day RO, Sutherland )]TJ
0 Tc 1.75 -1.25 Td
(RL. D-Penicillamine causes free radical-dependent inactivation of)Tj
T*
[(activator protein-1 DNA)-220.1 (binding. Mol Pharmacol 1996;50:501-5.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(46.)-500.1 (Flanagan )17.7 (WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear)]TJ
0 Tc 1.75 -1.25 Td
[(association of a )17.8 (T)91.8 (-cell transcription factor blocked by FK-506 and)]TJ
T*
[(cyclosporin )54.9 (A. Nature 1991;352:803-7.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 54.5 36.791 Tm
[(Lehmann, et al: Ster)36.9 (oids and synovial NF-)]TJ
/T1_0 1 Tf
0 Tw 8 0 1.7005 8 191.5985 36.791 Tm
(\002)Tj
/TT1 1 Tf
8 0 0 8 195.9891 36.791 Tm
(B)Tj
43.7514 -0.1321 Td
(795)Tj
ET
0 0 0 0 scn
/GS0 gs
101.73 58.75 407.5 -10.83 re
f*
0.5 w
101.73 58.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_1 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
129 0 obj
<>
endobj
168 0 obj
<>
endobj
192 0 obj
<>
endobj
138 0 obj
<>
endobj
130 0 obj
<>
endobj
127 0 obj
<>
endobj
157 0 obj
<>stream
HVpMg}9ބ(ysHJx%Wǽ"dRjLQ"CKW6m2]F=cv5H[U{! A5y9o9]T}k/`v UUgv-<
(Q>%Fp9cu
=,+xsO2*"je:w|C͞S&l$rl6g__^XP|U̙_iݡm{ż~xɄuN*2Z>+suvp2ZR-hPwp7QnHAFW= +wq,qgDN/ ^lDŨdd/\?8i|ui&^@_cj]pc0#U-aVp: _YBs,O#Eg@$ȧx'd5#p"f2;sbTlk+O&-`*yF|df5XG,VEC"p``)ƭg_U\b*rIgWq++jźVyfB0'c